ESLA insider transaction filings

Estrella Immunopharma, Inc. — 3 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-04-29. Screen ESLA transaction legs live →

FiledFormInsiderReported transactionsSource
2026-04-294Xu Jiandong — Chief Financial OfficerPurchase (P): 100 @ $1.04 · Purchase (P): 1,000 @ $1.16 · Purchase (P): 1,000 @ $1.33EDGAR
2025-02-144Liu Cheng — Chief Executive Officer, DirectorGrant/award (A): 490,796 (derivative) · Grant/award (A): 509,204 (derivative)EDGAR
2025-02-144Xu Jiandong — Chief Financial OfficerGrant/award (A): 490,796 (derivative) · Grant/award (A): 509,204 (derivative)EDGAR

Recent 8-K events — Estrella Immunopharma, Inc.

FiledFormItems reportedSource
2026-08-218-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2026-06-308-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-01-138-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2026-01-068-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2025-12-048-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-11-068-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2025-09-298-K8.01 — Other EventsEDGAR
2025-09-268-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2025-08-078-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2025-06-058-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ESLA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →